Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Jul 18;2007(3):CD006063.
doi: 10.1002/14651858.CD006063.pub2.

Rosiglitazone for type 2 diabetes mellitus

B Richter  1 , E Bandeira-Echtler, K Bergerhoff, C Clar, S H Ebrahim
Affiliations
Meta-Analysis

Rosiglitazone for type 2 diabetes mellitus

B Richter et al. Cochrane Database Syst Rev. .

Abstract

Background: Diabetes has long been recognised as a strong, independent risk factor for cardiovascular disease, a problem which accounts for approximately 70% of all mortality in people with diabetes. Prospective studies show that compared to their non-diabetic counterparts, the relative risk of cardiovascular mortality for men with diabetes is two to three and for women with diabetes is three to four. The two biggest trials in type 2 diabetes, the United Kingdom Prospective Diabetes Study (UKPDS) and the University Group Diabetes Program (UGDP) study did not reveal a reduction of cardiovascular endpoints through improved metabolic control. Theoretical benefits of the peroxisome proliferator activated receptor gamma (PPAR-gamma) activator rosiglitazone on endothelial function and cardiovascular risk factors might result in fewer macrovascular disease events in people with type 2 diabetes mellitus.

Objectives: To assess the effects of rosiglitazone in the treatment of type 2 diabetes.

Search strategy: Studies were obtained from computerised searches of MEDLINE, EMBASE and The Cochrane Library.

Selection criteria: Studies were included if they were randomised controlled trials in adult people with type 2 diabetes mellitus and had a trial duration of at least 24 weeks.

Data collection and analysis: Two authors independently assessed trial quality and extracted data. Pooling of studies by means of fixed-effects meta-analysis could be performed for adverse events only.

Main results: Eighteen trials which randomised 3888 people to rosiglitazone treatment were identified. Longest duration of therapy was four years with a median of 26 weeks. Published studies of at least 24 weeks rosiglitazone treatment in people with type 2 diabetes mellitus did not provide evidence that patient-oriented outcomes like mortality, morbidity, adverse effects, costs and health-related quality of life are positively influenced by this compound. Metabolic control measured by glycosylated haemoglobin A1c (HbA1c) as a surrogate endpoint did not demonstrate clinically relevant differences to other oral antidiabetic drugs. Occurrence of oedema was significantly raised (OR 2.27, 95% confidence interval (CI) 1.83 to 2.81). The single large RCT (ADOPT - A Diabetes Outcomes Progression Trial) indicated increased cardiovascular risk. New data on raised fracture rates in women reveal extensive action of rosiglitazone in various body tissues.

Authors' conclusions: New studies should focus on patient-oriented outcomes to clarify the benefit-risk ratio of rosiglitazone therapy. Safety data and adverse events of all investigations (published and unpublished) should be made available to the public.

PubMed Disclaimer

Conflict of interest statement

This review in part contributes to the ongoing critical appraisal of RCTs investigating the risk‐benefit ratio of thiazolidinedione use by the German Institute for Quality and Efficiency in Health Care ('Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen ‐ IQWiG).

Figures

1
1
QUOROM (quality of reporting of meta‐analyses) flow‐chart of study selection
1.1
1.1. Analysis
Comparison 1 Adverse events, Outcome 1 No. of patients experiencing oedema.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD006063

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Derosa 2004 {published data only}
    1. Derosa G, Cicero AFG, D'Angelo A, Gaddi A, Ragonesi PD, Piccinni MN, Salvadeo S, Ciccarelli L, Pricolo F, Ghelfi M, Ferrari I, Montagna L, Fogari R. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertension Research 2005;28(11):917‐924. - PubMed
    1. Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Fogari E, Bertone G, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve‐month, multicenter, double‐blind, randomized, controlled, parallel‐group trial. Clinical Therapeutics 2004;26(5):744‐54. - PubMed
    1. Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo S, Ciccarelli L, Fogari R. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Research & Clinical Practice 2005;69(1):5‐13. - PubMed
Derosa 2006a {published data only}
    1. Derosa G, Angelo AD, Ragonesi PD, Ciccarelli L, Piccini MN, Pricolo F, et al. Metformin‐pioglitazone and metformin‐rosiglitazone effects on non‐conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of Clinical Pharmacology and Therapeutics 2006;31:375‐83. - PubMed
    1. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal 2007;37:79‐86. - PubMed
Derosa 2006b {published data only}
    1. Derosa G, Cicero AFG, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, et al. Long‐term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12‐month, double‐blind, randomized trial. Clinical Therapeutics 2005;27(9):1383‐90. - PubMed
    1. Derosa G, Gaddi AV, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, et al. Long‐term effect of glimepiride and rosiglitazone on non‐conventional cardiovascular risk factors in metformin‐treated patients affected by metabolic syndrome: A randomized, double‐blind clinical trial. Journal of International Medical Research 2005;33(3):284‐94. - PubMed
    1. Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, et al. Antithrombotic effects of rosiglitazone‐metformin versus glimepiride‐metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy 2005;25(5 I):637‐45. - PubMed
    1. Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial. Diabetes, Obesity and Metabolism 2006;8:197‐205. - PubMed
Garber 2006 {published data only}
    1. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin‐glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes, Obesity and Metabolism 2006;8:156‐63. - PubMed
Goldberg 2005 {published data only}
    1. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28(7):1547‐54. - PubMed
Hanefeld 2007 {published data only}
    1. Hanefeld M, Patwardhan R, Jones NP, Rosiglitazone Clinical Trials Study Group. A one‐year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutrition, Metabolism, and Cardiovascular Diseases 2007;17(1):13‐23. - PubMed
Hällsten 2002 {published data only}
    1. Hällsten K, Virtanen KA, Lonnqvistt F, Janatuinen T, Turiceanu M, Ronnemaa T, et al. Enhancement of insulin‐stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabetic Medicine 2004;21(12):1280‐7. - PubMed
    1. Hällsten K, Virtanen KI, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, et al. Rosiglitazone but not metformin enhances insulin‐ and exercise‐stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002;51:3479‐85. - PubMed
    1. Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, et al. Effects of metformin and rosiglitazone monotherapy on insulin‐mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care. 26 2003; Vol. 26, issue 7:2069‐74. - PubMed
    1. Karlsson HK, Hallsten K, Bjornholm M, Tsuchida H, Chibalin AV, Virtanen KA, et al. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 2005;54(5):1459‐67. - PubMed
    1. Viljanen APM, Virtanen KA, Järvisalo MJ, Hällsten K, Parkkola R, Rönnemaa T, et al. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double‐blind, randomized study with metformin. Journal of Clinical Endocrinology & Metabolism 2005;90(12):6523‐8. - PubMed
Jung 2005 {published data only}
    1. Jung HS, Youn BS, Cho YM, Yu KY, Park HJ, Shin CS, et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental 2005;54(3):314‐20. - PubMed
Kahn 2006 {published data only}
    1. Correction to Kahn, et al. N Engl J Med 355(23):2427‐2443 December 7, 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 2007;356(13):1387‐8. - PubMed
    1. Gandhi GY, Montori VM. Glycemic durability of monotherapy for diabetes. New England Journal of Medicine 2007;356(13):1378‐80. - PubMed
    1. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 2006;355(23):2427‐43. - PubMed
    1. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes?. New England Journal of Medicine 2006;355(23):2477‐80. - PubMed
    1. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737‐43. - PubMed
Ko 2006 {published data only}
    1. Ko GT, Tsang PC, Wai HP, Kan EC, Chan HC. Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1‐year randomized clinical trial. Advances in Therapy 2006;23(5):799‐808. - PubMed
Lebovitz 2001 {published data only}
    1. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106(6):679‐84. - PubMed
    1. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 2001;86(1):280‐8. - PubMed
Ovalle 2004 {published data only}
    1. Ovalle F, Bell DSH. Effect of rosiglitazone versus insulin on the pancreatic beta‐cell function of subjects with type 2 diabetes. Diabetes Care 2004;27(11):2585‐9. - PubMed
Phillips 2001 {published data only}
    1. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once‐ and twice‐daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24(2):308‐15. - PubMed
Raskin 2004 {published data only}
    1. Raskin P, McGill J, Saad MF, Cappleman JM, Kaye W, Khutoryansky N et al ‐ for the Repaglinide/Rosiglitazone Study Group. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabetic Medicine 2004;21:329‐35. - PubMed
Rosenstock 2006b {published data only}
    1. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes‐Rak E, Dailey G ‐ on behalf of the Insulin Glargine 4014 Study Investigators. Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin‐naive patients. Diabetes Care 2006;29:554‐9. - PubMed
Stocker 2007 {published data only}
    1. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. American Heart Journal 2007;153(3):445.e1‐6. - PubMed
Sutton 2002 {published data only}
    1. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. Journal of Human Hypertension 2003;17(1):7‐12. - PubMed
    1. John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25(11):2058‐64. - PubMed
Yang 2002 {published data only}
    1. Yang W‐S, Jeng C‐Y, Wu T‐J, Tanaka S, Funahashi T, Matsuzawa Y, et al. Synthetic peroxisome proliferator‐activated receptor‐gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25(2):376‐80. - PubMed

References to studies excluded from this review

Bailey 2005 {published data only}
    1. Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, et al. Rosiglitazone/metformin fixed‐dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24‐week, multicenter, randomized, double‐blind, parallel‐group study. Clinical Therapeutics 2005;27(10):1548‐61. - PubMed
Baksi 2004 {published data only}
    1. Baksi A, James RE, Zhou B, Nolan JJ. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half‐maximal doses of a sulphonylurea. Acta Diabetologica 2004;41(2):63‐9. [MEDLINE: ] - PubMed
Barnett 2003 {published data only}
    1. Barnett AH, Grant PJ, Hitman GA, Mather H, Pawa M, Robertson L, et al. Rosiglitazone in Type 2 diabetes mellitus: An evaluation in British Indo‐Asian patients. Diabetic Medicine 2003;20(5):387‐93. - PubMed
Dailey 2004 {published data only}
    1. Dailey III GE, Noor MA, Park J‐S, Bruce S, Fiedorek FT. Glycemic control with Glyburide/Metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double‐blind trial. American Journal of Medicine 2004;116(4):223‐29. - PubMed
Fonseca 2000 {published data only}
    1. Desouza C, Fonseca VA. Insulin sensitizer combination therapy for type 2 diabetes. Cardiology Review 2001;18(1):11‐15.
    1. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. Journal of the American Medical Association 2000;283(13):1695‐1702. - PubMed
Fonseca 2003 {published data only}
    1. Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Research and Clinical Practice 2003;26(6):1685‐90. - PubMed
Gomez‐Perez 2002 {published data only}
    1. Gomez‐Perez FJ, Fanghanel‐Salmon G, Barbosa JA, Montes‐Villarreal J, Berry RA, Warsi G, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes/Metabolism Research Reviews 2002;18(2):127‐34. - PubMed
Hubacek 2004 {published data only}
    1. Hubacek J, Verma S, Shewchuk L, Ross SJ, Edwards A, Anderson TJ. Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes. Canadian Journal of Cardiology 2004;20(14):1449‐53. - PubMed
Kerenyi 2004 {published data only}
    1. Kerenyi Z, Samer H, James R, Yan Y, Stewart M. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2004;63(3):213‐23. - PubMed
McCluskey 2004 {published data only}
    1. McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D. Results of a randomized, double‐blind, placebo‐controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clinical Therapeutics 2004;26(11):1783‐90. - PubMed
Negro 2005 {published data only}
    1. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Research and Clinical Practice 2005;70:20‐5. - PubMed
Raskin 2001 {published data only}
    1. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J ‐ Rosiglitazone‐Clinical‐Trials‐Study‐Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin‐treated type 2 diabetes. Diabetes Care 2001;24:1226‐32. - PubMed
Reynolds 2002 {published data only}
    1. Reynolds LR, Konz EC, Frederich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long‐standing type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2002;4(4):270‐5. - PubMed
Rosenstock 2006a {published data only}
    1. Herman WH, Dirani RG, Horblyuk R, O'Neill MC, Kravitz B, Heise MA et al ‐ and the RESULT Study Group. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) Study. American Journal of Managed Care 2005;11(4):273‐8. - PubMed
    1. Rosenstock J, Goldstein BJ, Vinik AI, O'Neill MO, Porter LE, Heise MA et al ‐ and the RESULT Study Group. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs SULphonylurea Titration (RESULT) study. Diabetes, Obesity and Metabolism 2006;8:49‐57. - PubMed
Tan 2005a {published data only}
    1. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 2005;48(1):83‐95. - PubMed
Tan 2005b {published data only}
    1. Tan GD, Debard C, Funahashi T, Humphreys SM, Matsuzawa Y, Frayn KN, et al. Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia 2005;48(8):1585‐9. - PubMed
Vongthavaravat 2002 {published data only}
    1. Vongthavaravat V, Wajchenberg BL, Waitman JN, Quimpo JA, Menon PS, Ben KF, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Current Medical Research and Opinion 2002;18(8):456‐61. - PubMed
Wang 2005 {published data only}
    1. Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X. Peroxisome proliferator‐activated receptor‐gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 2005;54(5):590‐7. - PubMed
Weissman 2005 {published data only}
    1. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Current Medical Research and Opinion 2005;21(12):2029‐35. - PubMed
Wolffenbuttel 2000 {published data only}
    1. Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabetic Medicine 2000;17(1):40‐7. - PubMed
Wong 2005 {published data only}
    1. Wong TYH, Szeto CC, Chow KM, Leung CB, Lam CWK, Li PKT. Rosiglitazone reduces insulin requirements and c‐reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. American Journal of Kidney Diseases 2005;46(4):713‐9. - PubMed
Zhu 2003 {published data only}
    1. Zhu X‐X, Pan C‐Y, Li G‐W, Shi H‐L, Tian H, Yang W‐Y, et al. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technology & Therapeutics 2003;5(1):33‐42. - PubMed

References to ongoing studies

RECORD {published data only}
    1. Home PD, Pocock SJ, Beck‐Nielsen H, Gomis R, Hanefeld M, Dargie H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005;48:1726‐35. - PubMed

Additional references

ADA 1997
    1. American Diabetes Association. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20 Suppl 1:S5‐20. - PubMed
ADA 1999
    1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 Suppl 1:S5‐19. - PubMed
Ali 2005
    1. Ali AA, Weinstein RA, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226‐35. - PubMed
Armour 2004
    1. Armour T, Norris S, Brown D, Zhang X, Caspersen C. Initiating and maintaining physical activity for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2004, Issue 1.
Black 2003
    1. Black C, McIntyre L, Mesa‐Perez JA, Royle PL, Thomas S, Waugh N. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2003, Issue 4. - PMC - PubMed
Bloomgarden 2005
    1. Bloomgarden ZT. Thiazolidinediones. Diabetes Care 2005;28(2):488‐93. - PubMed
Boucher 2002
    1. Boucher M, McAuley L, Brown A, Keely E, Skidmore B. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti‐diabetic agents. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment, 2002.
Boucher 2003
    1. Boucher M, McAuley L, Brown A, Keely E, Skidmore B. Efficacy of rosiglitazone and pioglitazone compared to other anti‐diabetic agents: systematic review and budget impact analysis. Ottawa, Canada: Canadian Office for Health Technology Assessment, 2003.
Burt 2005
    1. Burt AL, Green S, Kwan I, Mugglestone M, Thomas J. Intranasal insulin for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 2.
Chiquette 2004
    1. Chiquette E, Ramirez G, DeFronzo R. A meta‐analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Archives of Internal Medicine 2004;164(19):2097‐104. - PubMed
Cohen 1960
    1. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37‐46.
Colucciello 2005
    1. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Archives of Ophthalmology 2005;123(9):1273‐5. - PubMed
Cox 2004
    1. Cox SL. Rosiglitazone maleate/metformin hydrochloride: A new formulation therapy for type 2 diabetes. Drugs of Today 2004;40(7):633‐43. - PubMed
Czoski‐Murray 2004
    1. Czoski‐Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J. Clinical effectiveness and cost‐effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: A systematic review and economic evaluation. Winchester, England: Health Technology Assessment, 2004. - PubMed
DCCT 1993
    1. The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The New England Journal of Medicine 1993;329(14):977‐86. - PubMed
DeFronzo 1992
    1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992;15:318‐68. - PubMed
Dormandy 2005
    1. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi‐Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet 2005;366(9493):1279‐89. - PubMed
Ewart 2001
    1. Ewart RM. The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study. BMJ 2001;323(7317):854‐8. - PMC - PubMed
Freemantle 2003
    1. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 2003;289(19):2554‐9. - PubMed
Gimenez‐Perez 2001
    1. Gimenez‐Perez G, Gonzalez‐Clemente JM, Mauricio D. Lifestyle interventions for preventing type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2001, Issue 1.
Grey 2007
    1. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, et al. The peroxisome proliferator‐activated receptor‐gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism 92;4:1305‐10. - PubMed
Haffner 1998
    1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine 1998;339:229‐34. - PubMed
HDS 1993
    1. The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. Journal of Hypertension 1993;11:309‐17. - PubMed
Higgins 2002
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in medicine 2002;21:1539‐58. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analysis. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2005
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
Kahn 1997
    1. Kahn SE, Porte D Jr. The pathophysiology of type II (noninsulindependent) diabetes mellitus: implications for treatment. In: Porte D Jr, Sherwin RS editor(s). Ellenberg & Rifkin's Diabetes Mellitus. 5th Edition. Stamford, Conneticut (U.S.A.): Appleton & Lange, 1997.
Kreider 2002
    1. Kreider M, Heise M. Rosiglitazone in the management of older patients with type 2 diabetes mellitus. International Journal of Clinical Practice 2002;56(7):538‐41. - PubMed
Laakso 1999
    1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999;48:937‐42. - PubMed
Lau 2006
    1. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597‐600. - PMC - PubMed
Lazarenko 2007
    1. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka‐Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007;148(6):2669‐80. - PMC - PubMed
Lebovitz 2002
    1. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25:815‐21. - PubMed
Lindberg 2002
    1. Lindberg G, Lindblad U, Melander A. Sulfonylureas for treating type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2002, Issue 4.
Malinowski 2000
    1. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review. Clinical Therapeutics 2000;22(10):1151‐68. - PubMed
Manson 1991
    1. Manson JE, Coldlitz GA, Stampfer MJ, Willet WC, Krolewski AS, Rosner B, et al. A prospective study of maturity‐onset diabetes mellitus and risk of coronary heart disease and stroke in women. Archives of Internal Medicine 1991;151:1141‐7. - PubMed
Marcy 2004
    1. Marcy TR, Britton ML, Blevins SM. Second‐generation thiazolidinediones and hepatotoxicity. The Annals of Pharmacotherapy 2004;38(9):1419‐23. - PubMed
McAlister 2003
    1. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003;289(19):2545‐53. - PubMed
McCormack 2003
    1. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ 2000;320(7251):1720‐3. - PMC - PubMed
Menees 2005
    1. Menees SB, Anderson MA, Chensue SW, Moseley RH. Hepatic injury in a patient taking rosiglitazone. Journal of Clinical Gastroenterology 2005;39(7):638‐40. - PubMed
Meriden 2004
    1. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clinical Therapeutics 2004;26(2):177‐90. - PubMed
Misso 2005
    1. Misso ML, O'Connor DA, Egberts KJ, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 1. - PubMed
Moher 1999
    1. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta‐analyses. Lancet 1999;354(9193):1896‐900. - PubMed
Montgomery 2003
    1. Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. BMJ 2003;3:26. - PMC - PubMed
Moore 2005
    1. Moore H, Summerbell C, Hooper, L, Ashton V, Kopelman P. Dietary advice for the prevention of type 2 diabetes mellitus in adults. Cochrane Database of Systematic Reviews 2005, Issue 1. - PubMed
Mukhtar 2005
    1. Mukhtar R, Reckless JPD. Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. Diabetic Medicine 2005;22:6‐10. - PubMed
Nathan 1998
    1. Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 1998;352(9131):832‐3. - PubMed
NICE 2000
    1. Guidance on rosiglitazone for Type 2 diabetes mellitus. London: National Institute for Clinical Excellence, 2000.
NICE 2003
    1. Guidance on the use of glitazones for the treatment of type 2 diabetes. London: National Institute for Clinical Excellence, 2003.
NICE 2003b
    1. Review of rosiglitazone and pioglitazone for type II diabetes ‐ appraisal (project). London: National Institute for Clinical Excellence, 2003.
Nissen 2007
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007;356:www.nejm.org (10.1056/NEJMoa072761). - PubMed
Ohkubo 1995
    1. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent mellitus: a randomized prospective 6‐year study. Diabetes Research and Clinical Practice 1995;28:103‐17. - PubMed
Psaty 2007
    1. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. New England Journal of Medicine 2007;356:www.nejm.org (10.1056/NEJMe078099). - PubMed
Richter 2005
    1. Richter B, Neises G. 'Human' insulin versus animal insulin in people with diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 1. - PMC - PubMed
Richter 2006
    1. Richter B, Bandeira‐Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 4. - PMC - PubMed
Richter 2007
    1. Richter B, Bandeira‐Echtler E, Bergerhoff K. Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 3. - PMC - PubMed
Roberts 2005
    1. Roberts D, Van NW, Chang H, Pohula W, MCheang, Moffatt M, et al. Glargine versus other basal insulins (NPH, Lente, or Ultralente) for the treatment of type 1 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 2.
Royle 2003
    1. Royle P, Waugh N, McAuley L, McIntyre L, Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database of Systematic Reviews 2003, Issue 4. - PubMed
Ruige 1997
    1. Ruige JB, deNeeling JND, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 1997;20:491–6. - PubMed
Saenz 2005
    1. Saenz A, Fernandez‐Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 3. - PubMed
Salpeter 2003
    1. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2003, Issue 3. - PubMed
Schwartz 2006a
    1. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka‐Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. Journal of Clinical Endocrinology and Metabolism 2006;91:3349‐54. - PMC - PubMed
Schwartz 2006b
    1. Schwartz AV. Diabetes, TZDs, and bone: A review of the clinical evidence. PPAR Research 2006;19:1‐6. - PMC - PubMed
Siebenhofer 2004
    1. Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2004, Issue 4. - PubMed
Snaith 2007
    1. Snaith A, McIntyre L, Rothnie H, Thomas S, Royle P, Waugh N. Glucagon‐like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 1.
Stamler 1993
    1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12‐year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434‐44. - PubMed
Sterne 2001
    1. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta‐analysis in Context. London: BMJ Publishing Group, 2001:189‐208.
Stratton 2000
    1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405‐12. - PMC - PubMed
Su 2006
    1. Su DH, Lai MY, Wu HP. Liver failure in a patient receiving rosiglitazone therapy. Diabetic Medicine 2006;23(1):105‐6. - PubMed
Tang 2000
    1. Tang JL, Liu JLY. Misleading funnel plot for detection of bias in meta‐analysis. Journal of Clinical Epidemiology 2000;53:477‐84. - PubMed
Thomas 2001
    1. Thomas D, Elliott E. Exercise for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2001, Issue 1. - PMC - PubMed
Thornton 2000
    1. Thornton A, Lee P. Publication bias in meta‐analysis: its causes and consequences. Journal of Clinical Epidemiology 2000;53:207‐16. - PubMed
UGDP 1982
    1. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult‐onset diabetes, VIII. Evaluation of insulin therapy: final report. Diabetes 1982;31 Suppl 5:1‐81. - PubMed
UKPDS‐16 1995
    1. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249‐58. - PubMed
UKPDS‐33 1998
    1. UK Prospective Diabetes Study Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes‐UKPDS 33. Lancet 1998;352:837‐52. - PubMed
UKPDS‐34 1998
    1. UK Prospective Diabetes Study Group. Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352:854‐65. - PubMed
UKPDS‐38 1998
    1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703‐13. - PMC - PubMed
Van de Laar 2005
    1. Laar FA, Lucassen PLBJ, Akkermans RP, Lisdonk EH, Rutten GEHM, Van WC. Alpha‐glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 2. - PMC - PubMed
Wagstaff 2002
    1. Wagstaff AJ, Goa KL. Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs 2002;62(12):1805‐37. - PubMed
Warram 1990
    1. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of Type 2 diabetes in the offspring of diabetic parents. Annals of Internal Medicine 1990;113:909–15. - PubMed
Wellington 2005
    1. Wellington K. Rosiglitazone/Metformin. Drugs 2005;65(11):1581‐92. - PubMed
WHO 1980
    1. WHO Expert Committee on Diabetes Mellitus. Geneva: World Health Organisation, 1980. Second report. Technical Report Series 646. - PubMed
WHO 1985
    1. WHO Expert Committee on Diabetes Mellitus. Geneva: World Health Organization, 1985. Technical Report Series 727.. - PubMed
WHO 1998
    1. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539‐53. - PubMed
Yang 2001
    1. Yang C, Chang TJ, Chang JC, Liu MW, Tai TY, Hsu WH, et al. Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3‐kinase pathway. Diabetes 2001;50:2598‐602. - PubMed
Yaturu 2007
    1. Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007;0:dc06‐2606v1‐0. - PubMed